Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofazimine - Novartis

Next Previous
X
Search
Drug Profile

Clofazimine - Novartis

Alternative Names: B-663; LAM-320; Lamprene

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College Dublin
  • Developer Alliance Pharma plc; Novartis; University College Dublin; University of Pretoria
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leprosy; Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy
  • No development reported Nontuberculous mycobacterium infections
  • Discontinued Crohn's disease; Liver cancer; Tuberculosis

Most Recent Events

  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in Nontuberculous-mycobacterium-infections(Treatment-experienced) in USA (PO, Capsule)
  • 06 May 2021 Discontinued - Phase-III for Tuberculosis (Treatment-resistant) (PO)
  • 03 Apr 2020 Clinical trials in Nontuberculous mycobacterium infections (Treatment-experienced) in USA (PO) (NCT04334070)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top